Advertisement

Breast Cancer Research and Treatment

, Volume 151, Issue 1, pp 141–147 | Cite as

Aromatase inhibitors in male breast cancer: a pooled analysis

  • Flora ZagouriEmail author
  • Theodoros N. Sergentanis
  • Hatem A. AzimJr.
  • Dimosthenis Chrysikos
  • Meletios-Athanassios Dimopoulos
  • Theodora Psaltopoulou
Epidemiology

Abstract

Although several studies have shown the efficacy of third-generation aromatase inhibitors (AIs) in women with breast cancer, the role of such molecules remains elusive in male breast cancer patients. It is also unknown whether the addition of gonadotropin-releasing hormone (GnRH) analogues to AIs would be a superior strategy or not. This pooled analysis was conducted in accordance with the PRISMA guidelines. All studies that examined the efficacy of AIs in metastatic male breast cancer were considered eligible. Overall, 15 studies (105 cases) were eligible for this pooled analysis. The mean age of the study sample was 62.8 years. ER status was positive in all eligible cases. AI was given as first line in 61.5 % of cases. GnRH analogue was co-administered with AI in 37.1 % of cases (n = 39). CR, PR, SD and PD were achieved in 5.7, 23.8, 37.2 and 33.3 % of cases, respectively. The median PFS and OS were equal to 10.0 and 39.0 months, respectively. Co-administration of GnRH analogues was associated with more than threefold increase in rates of clinical benefit (OR = 3.37, 95 % CI 1.30–8.73) but did not seem to correlate with better PFS or OS. No statistically significant associations between the examined outcomes and the other parameters were noted. Available data suggest that AIs may potentially play a promising role in the optimal therapeutic strategy for metastatic male breast cancer patients. Especially, co-administration of AI with a GnRH analogue seems to increase the rate of clinical benefit and could be more effective, warranting further consideration.

Keywords

Male breast cancer Aromatase inhibitors Hormonal treatment GnRH analogues 

Notes

Conflict of interest

The authors have declared no conflicts of interest.

Supplementary material

10549_2015_3356_MOESM1_ESM.docx (56 kb)
Supplementary Table 1 (DOCX 57 kb)
10549_2015_3356_MOESM2_ESM.docx (33 kb)
Supplementary Table 2 (DOCX 33 kb)

References

  1. 1.
    Brinton LA, Richesson DA, Gierach GL, Lacey JV Jr, Park Y, Hollenbeck AR, Schatzkin A (2008) Prospective evaluation of risk factors for male breast cancer. J Natl Cancer Inst 100:1477–1481CrossRefPubMedCentralPubMedGoogle Scholar
  2. 2.
    Eggemann H, Ignatov A, Smith BJ, Altmann U, von Minckwitz G, Röhl FW, Jahn M, Costa SD (2013) Adjuvant therapy with tamoxifen compared to aromatase inhibitors for 257 male breast cancer patients. Breast Cancer Res Treat 137:465–470CrossRefPubMedGoogle Scholar
  3. 3.
    NCCN Clinical Practice Guidelines in Oncology. Breast Cancer. Version 3.2014. Available at www.nccn.com
  4. 4.
    Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van’t Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Ann Oncol 25:1871–1888CrossRefPubMedCentralPubMedGoogle Scholar
  5. 5.
    Cardoso F, Costa A, Norton L, Senkus E, Aapro M, André F, Barrios CH, Bergh J, Biganzoli L, Blackwell KL, Cardoso MJ, Cufer T, El Saghir N, Fallowfield L, Fenech D, Francis P, Gelmon K, Giordano SH, Gligorov J, Goldhirsch A, Harbeck N, Houssami N, Hudis C, Kaufman B, Krop I, Kyriakides S, Lin UN, Mayer M, Merjaver SD, Nordström EB, Pagani O, Partridge A, Penault-Llorca F, Piccart MJ, Rugo H, Sledge G, Thomssen C, Van’t Veer L, Vorobiof D, Vrieling C, West N, Xu B, Winer E (2014) ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2). Breast 23:489–502CrossRefPubMedGoogle Scholar
  6. 6.
    Jordan VC, Obiorah I, Fan P, Kim HR, Ariazi E, Cunliffe H, Brauch H (2011) The St. Gallen Prize evolution of long-term adjuvant anti-hormone therapy: consequences and opportunities. Breast 20(Suppl 3):S1–S11PubMedCentralPubMedGoogle Scholar
  7. 7.
    Regan MM, Neven P, Giobbie-Hurder A, Goldhirsch A, Ejlertsen B, Mauriac L, Forbes JF, Smith I, Láng I, Wardley A, Rabaglio M, Price KN, Gelber RD, Coates AS, Thürlimann B, BIG 1–98 Collaborative Group; International Breast Cancer Study Group (IBCSG) (2011) Assessment of letrozole and tamoxifen alone and in sequence for postmenopausal women with steroid hormone receptor-positive breast cancer: the BIG 1–98 randomised clinical trial at 8.1 years median follow-up. Lancet Oncol 12:1101–1108CrossRefPubMedCentralPubMedGoogle Scholar
  8. 8.
    Cuzick J, Sestak I, Baum M, Buzdar A, Howell A, Dowsett M, Forbes JF, ATAC, LATTE investigators (2011) Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 10-year analysis of the ATAC trial. Lancet Oncol 11:1135–1141CrossRefGoogle Scholar
  9. 9.
    Bliss JM, Kilburn LS, Coleman RE, Forbes JF, Coates AS, Jones SE, Jassem J, Delozier T, Andersen J, Paridaens R, van de Velde CJ, Lønning PE, Morden J, Reise J, Cisar L, Menschik T, Coombes RC (2012) Disease-related outcomes with long-term follow-up: an updated analysis of the intergroup exemestane study. J Clin Oncol 30:709–717CrossRefPubMedGoogle Scholar
  10. 10.
    Soon Wong N, Seong Ooi W, Pritchard KI (2007) Role of gonadotropin-releasing hormone analog in the management of male metastatic breast cancer is uncertain. J Clin Oncol 25:3787CrossRefPubMedGoogle Scholar
  11. 11.
    Giordano SH, Hortobagyi GN (2006) Leuprolide acetate plus aromatase inhibition for male breast cancer. J Clin Oncol 24:e42–e43CrossRefPubMedGoogle Scholar
  12. 12.
    Onami S, Ozaki M, Mortimer JE, Pal SK (2010) Male breast cancer: an update in diagnosis, treatment and molecular profiling. Maturitas 65:308–314CrossRefPubMedCentralPubMedGoogle Scholar
  13. 13.
    Turner KJ, Morley M, Atanassova N, Swanston ID, Sharpe RM (2000) Effect of chronic administration of an aromatase inhibitor to adult male rats on pituitary and testicular function and fertility. J Endocrinol 164:225–238CrossRefPubMedGoogle Scholar
  14. 14.
    Mauras N, O’Brien KO, Klein KO, Hayes V (2000) Estrogen suppression in males: metabolic effects. J Clin Endocrinol Metab 85:2370–2377PubMedGoogle Scholar
  15. 15.
    Liberati A, Altman DG, Tetzlaff J (2009) The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 62:e1–e34CrossRefPubMedGoogle Scholar
  16. 16.
    Katayama K, Yamagishi J, Kashiwagi B (2013) A case of male breast cancer for which mTOR inhibitor was effective with advanced renal cancer. Gan To Kagaku Ryoho 40:365–369PubMedGoogle Scholar
  17. 17.
    Chen F, Qiu L (2014) Biological and clinical implications of aromatase inhibitors in early male breast cancer patients. Zhonghua Yi Xue Za Zhi 94:273–275PubMedGoogle Scholar
  18. 18.
    White J, Kearins O, Dodwell D, Horgan K, Hanby AM, Speirs V (2011) Male breast carcinoma: increased awareness needed. Breast Cancer Res 13:219CrossRefPubMedCentralPubMedGoogle Scholar
  19. 19.
    Visram H, Kanji F, Dent SF (2010) Endocrine therapy for male breast cancer: rates of toxicity and adherence. Curr Oncol 17:17–21PubMedCentralPubMedGoogle Scholar
  20. 20.
    Harlan LC, Zujewski JA, Goodman MT, Stevens JL (2010) Breast cancer in men in the United States: a population-based study of diagnosis, treatment, and survival. Cancer 116:3558–3568CrossRefPubMedCentralPubMedGoogle Scholar
  21. 21.
    Cutuli B, Le-Nir CC, Serin D, Kirova Y, Gaci Z, Lemanski C, De Lafontan B, Zoubir M, Maingon P, Mignotte H, de Lara CT, Edeline J, Penault-Llorca F, Romestaing P, Delva C, Comet B, Belkacemi Y (2010) Male breast cancer. Evolution of treatment and prognostic factors. Analysis of 489 cases. Crit Rev Oncol Hematol 73:246–254CrossRefPubMedGoogle Scholar
  22. 22.
    Horimoto Y, Hino M, Saito M, Arakawa A, Matsumoto T, Kasumi F (2008) Bilateral nonsynchronous male breast cancer: two case reports. Breast Care (Basel) 3:51–53CrossRefGoogle Scholar
  23. 23.
    Bradley KL, Tyldesley S, Speers CH, Woods R, Villa D (2014) Contemporary systemic therapy for male breast cancer. Clin Breast Cancer 14:31–39CrossRefPubMedGoogle Scholar
  24. 24.
    Di Lauro L, Vici P, Del Medico P, Laudadio L, Tomao S, Giannarelli D, Pizzuti L, Sergi D, Barba M, Maugeri-Saccà M (2013) Letrozole combined with gonadotropin-releasing hormone analog for metastatic male breast cancer. Breast Cancer Res Treat 141:119–123CrossRefPubMedGoogle Scholar
  25. 25.
    Zagouri F, Sergentanis TN, Koutoulidis V, Sparber C, Steger GG, Dubsky P, Zografos GC, Psaltopoulou T, Gnant M, Dimopoulos MA, Bartsch R (2013) Aromatase inhibitors with or without gonadotropin-releasing hormone analogue in metastatic male breast cancer: a case series. Br J Cancer 108:2259–2263CrossRefPubMedCentralPubMedGoogle Scholar
  26. 26.
    Bighin C, Lunardi G, Del Mastro L, Marroni P, Taveggia P, Levaggi A, Giraudi S, Pronzato P (2010) Estrone sulphate, FSH, and testosterone levels in two male breast cancer patients treated with aromatase inhibitors. Oncologist 15:1270–1272CrossRefPubMedCentralPubMedGoogle Scholar
  27. 27.
    Montero AJ, Talebi TN, Zhu Y, Branch KD, Goldsberry GT, Baker MK, Gluck S (2011) Successful use of biweekly gemcitabine plus nab-paclitaxel in two male patients with stage iv breast cancer: case reports and review of the literature. Am J Ther 18:e12–e18CrossRefPubMedGoogle Scholar
  28. 28.
    Doyen J, Italiano A, Largillier R, Ferrero JM, Fontana X, Thyss A (2010) Aromatase inhibition in male breast cancer patients: biological and clinical implications. Ann Oncol 21:1243–1245CrossRefPubMedGoogle Scholar
  29. 29.
    Fontana S, Ghilardi R, Barbaglio A, Amaddeo P, Faldi F, Pericotti S (2007) Male breast cancer with mandibular metastasis. A case reports. Minerva Stomatol 56:225–230PubMedGoogle Scholar
  30. 30.
    Arriola E, Hui E, Dowsett M, Smith IE (2007) Aromatase inhibitors and male breast cancer. Clin Transl Oncol 9:192–194CrossRefPubMedGoogle Scholar
  31. 31.
    Carmona-Bayonas A (2007) Potential benefit of maintenance trastuzumab and anastrozole therapy in male advanced breast cancer. Breast 16:323–325CrossRefPubMedGoogle Scholar
  32. 32.
    Zabolotny BP, Zalai CV, Meterissian SH (2005) Successful use of letrozole in male breast cancer: a case report and review of hormonal therapy for male breast cancer. J Surg Oncol 90:26–30CrossRefPubMedGoogle Scholar
  33. 33.
    Giordano SH, Valero V, Buzdar AU, Hortobagyi GN (2002) Efficacy of anastrozole in male breast cancer. Am J Clin Oncol 25:235–237CrossRefPubMedGoogle Scholar
  34. 34.
    Italiano A, Largillier R, Marcy PY, Foa C, Ferrero JM, Hartmann MT, Namer M (2004) Complete remission obtained with letrozole in a man with metastatic breast cancer. Rev Med Interne 25:323–324CrossRefPubMedGoogle Scholar
  35. 35.
    Arrighi G, Cresti N, Donati S, Ricci S, Michelotti A, Ospedaliera A, Pisana U, Aromatase inhibitos in male breast cancer (2005) Abstract A17. 7TH National Congrss of Medical Oncology. Naples, Italy. Ann Oncol 16(Suppl. 7):vii 11Google Scholar
  36. 36.
    Baumgärtner AK, Schnelzer AC, Harbeck N, Kiechle M, von Steinburg SP (2007) Endocrine combination therapy for prostate and metastatic breast cancer in a male patient. Breast Care 2:37–39CrossRefGoogle Scholar
  37. 37.
    Kantarjian H, Yap HY, Hortobagyi G, Buzdar A, Blumenschein G (1983) Hormonal therapy for metastatic male breast cancer. Arch Intern Med 143:237–240CrossRefPubMedGoogle Scholar
  38. 38.
    Doberauer C, Niederle N, Schmidt CG (1988) Advanced male breast cancer treatment with the LH-RH analogue buserelin alone or in combination with the antiandrogen flutamide. Cancer 62:474–478CrossRefPubMedGoogle Scholar
  39. 39.
    Labrie F, Dupont A, Bélanger A, Lacourcière Y, Béland L, Cusan L, Lachance R (1990) Complete response to combination therapy with an LHRH agonist and flutamide in metastatic male breast cancer: a case report. Clin Invest Med 13:275–278PubMedGoogle Scholar
  40. 40.
    Kogire M, Yoshida A, Noda H, Asano M, Yamada T, Kitamura O, Matsumoto M (1985) A case of advanced male breast cancer treated effectively with estrogen. Gan No Rinsho 31:865–869PubMedGoogle Scholar
  41. 41.
    Zagouri F, Sergentanis TN, Chrysikos D, Zografos E, Rudas M, Steger G, Zografos G, Bartsch R (2013) Fulvestrant and male breast cancer: a case series. Ann Oncol 24:265–266CrossRefPubMedGoogle Scholar
  42. 42.
    Zagouri F, Sergentanis TN, Chrysikos D, Dimopoulos MA, Psaltopoulou T (2015) Fulvestrant and male breast cancer: a pooled analysis. Breast Cancer Res Treat 149:269–275CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2015

Authors and Affiliations

  • Flora Zagouri
    • 1
    Email author
  • Theodoros N. Sergentanis
    • 2
  • Hatem A. AzimJr.
    • 3
  • Dimosthenis Chrysikos
    • 1
  • Meletios-Athanassios Dimopoulos
    • 1
  • Theodora Psaltopoulou
    • 2
  1. 1.Department of Clinical Therapeutics, Alexandra Hospital, Medical SchoolUniversity of AthensAthensGreece
  2. 2.Department of Hygiene, Epidemiology and Medical Statistics, Medical SchoolUniversity of AthensAthensGreece
  3. 3.Department of Medicine, BrEAST Data Centre, Institut Jules BordetUniversité Libre de BruxellesBrusselsBelgium

Personalised recommendations